Pandemic News and Research

RSS

A pandemic is a global disease outbreak. During a pandemic, transmission can be anticipated in the workplace, not only from patient to workers in health care settings, but also among co-workers in general work settings. A pandemic would cause high levels of illness, death, social disruption, and economic loss. Everyday life would be disrupted because so many people in so many places become seriously ill at the same time. Impacts could range from school and business closings to the interruption of basic services such as public transportation and food delivery.

Sinovac Biotech receives Drug Registration Certificate for seasonal influenza vaccine

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that Sinovac Biotech (Hong Kong) Ltd., its wholly owned subsidiary company in Hong Kong, has received the Certificate of Drug/Product Registration from the Hong Kong Department of Health for its seasonal influenza vaccine Anflu.

25 Oct 2010

New research shows flu virus with D222G mutation can cause pneumonia

A variant of last year's pandemic influenza linked to fatal cases carried a mutation that enabled it to infect a different subset of cells lining the airway, according to new research. The study, due to be published next week in the Journal of Virology, suggests that the mutant virus could have impaired the lungs' ability to clear out germs.

25 Oct 2010

Baxter third quarter net income increases 12% to $595 million

Baxter International Inc. today announced its financial results for the third quarter of 2010, and provided its fourth quarter and updated full-year 2010 financial outlook.

From Baxter International Inc. 21 Oct 2010

BioCryst to present intravenous peramivir data for influenza treatment at IDSA meeting

BioCryst Pharmaceuticals, Inc. announced the presentation of data related to intravenous (i.v.) peramivir for the treatment of influenza at the 48th Annual Infectious Diseases Society of America (IDSA) meeting being held in Vancouver, Canada.

21 Oct 2010

IRB approves CEL-SCI’s Multikine Phase III clinical trial for head and neck cancer

CEL-SCI Corporation announced today it has received approval from seven hospital Institutional Review Boards in India to begin enrollment of subjects for a Phase III clinical trial of Multikine, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer.

21 Oct 2010

Gilead Sciences third quarter total revenues increase 8% to $1.94 billion

Gilead Sciences, Inc. announced today its results of operations for the quarter ended September 30, 2010. Total revenues for the third quarter of 2010 were $1.94 billion, up 8 percent compared to total revenues of $1.80 billion for the third quarter of 2009. Net income for the third quarter of 2010 was $704.9 million, or $0.83 per diluted share, compared to net income for the third quarter of 2009 of $673.0 million, or $0.72 per diluted share.

20 Oct 2010

Egg allergy is no reason to avoid 2010-2011 flu vaccination

Having an egg allergy is not a reason to avoid getting the 2010-2011 flu vaccination.

19 Oct 2010

Biocon, Pfizer enter global agreement to commercialize Insulin analog products

Biocon, Asia's premier biotechnology company, and Pfizer Inc. (NYSE: PFE), the world's leading biopharmaceutical company, today announced that they have entered into a strategic global agreement for the worldwide commercialization of Biocon's biosimilar versions of Insulin and Insulin analog products: Recombinant Human Insulin, Glargine, Aspart and Lispro.

18 Oct 2010

Oseltamivir reduces mortality in influenza A/H5N1 patients

A study published in the Journal of Infectious Diseases indicates that treatment with oseltamivir significantly reduces mortality in patients with influenza A/H5N1, or 'bird flu', even when given late in the course of illness.

15 Oct 2010

Medicago and PATH partner on development of broad coverage influenza vaccine

Medicago Inc., a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has been awarded $946,000 in funding by U.S.-based PATH pursuant to a research collaboration agreement. Medicago and PATH will work together on a broad coverage influenza vaccine based on Medicago's proprietary plant-based Virus-Like Particle (VLP) technologies for the developing world.

13 Oct 2010

New evidence supports possible link between XMRV and prostate cancer

Xenotropic murine leukemia virus-related virus (XMRV) has been the subject of many studies since its discovery in 2006, but conflicting reports have created an unclear picture of XMRV's role in human disease. In three recent studies published in the November 15 issue of The Journal of Infectious Diseases, now available online, the evidence supports a possible link between XMRV and prostate cancer but not other links involving chronic fatigue syndrome, HIV infection, or hepatitis C virus (HCV) infection.

13 Oct 2010

CEL-SCI receives Taiwanese IRB approval for Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation announced today it has received approval from the first Taiwanese Institutional Review Board ("IRB") to begin enrollment of subjects for a Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. An IRB is a group formally designated by an institution to review and monitor research involving human subjects and to ensure protection of their rights and welfare.

13 Oct 2010

Loyola continues mandatory employee flu-vaccination policy for second straight year

The best way to prevent the spread of the flu to patients in a medical setting would be to require all health-care workers to get an annual flu shot, says the American Academy of Pediatrics.

12 Oct 2010

BiondVax commences Multimeric-001 flu vaccine Phase IIa clinical study

BiondVax Pharmaceuticals Ltd., an Israeli biopharmaceutical company at the forefront of global efforts towards the development of a Universal Influenza Vaccine, today announced that it has begun to immunize subjects in a Phase IIa clinical trial of the Multimeric-001 Universal Flu Vaccine candidate. The study will evaluate the safety and immunogenicity of the Multimeric-001 vaccine.

11 Oct 2010

HHS awards Sanofi Pasteur 3-year, $56.94M egg supply contract for pandemic vaccine preparedness

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, has been awarded a three-year contract for $56.94 million by the U.S. Department of Health and Human Services (HHS) to maintain flocks to enable manufacturing pandemic influenza vaccine at full capacity on a year-round basis.

11 Oct 2010

Scientists proves Yersinia pestis as causative agent for Black Death epidemics in European continent

The latest tests conducted by anthropologists at the Johannes Gutenberg University Mainz (JGU) have proven that the bacteria Yersinia pestis was indeed the causative agent behind the "Black Death" that raged across Europe in the Middle Ages. The cause of the epidemic has always remained highly controversial and other pathogens were often named as possible causes, in particular for the northern European regions.

11 Oct 2010

Flu season looking 'typical,' CDC says

Flu activity in the Southern Hemisphere, where the flu season is ending, has been 'typical,' the federal Centers for Disease Control and Prevention said Thursday. All three types of flu that normally circulate are present, although the H1N1 'swine flu' strain that caused last year's pandemic has replaced the seasonal H1N1 strain that circulated before 2009.

11 Oct 2010

“Black Death” of the Middle ages blamed on bacteria

Black Death or plague that killed an estimated one-third of Europe's population in the Middle Ages has been ascribed to a bacteria called Yersinia pestis by anthropologists.

10 Oct 2010

CDC issues new universal influenza vaccination recommendation for all Americans

With the influenza vaccine already available and more supply anticipated than ever before, the National Foundation for Infectious Diseases convened ten of the country's leading medical and public health groups to call on all Americans to get vaccinated this season.

8 Oct 2010

Emergent BioSolutions and TLV form new joint venture to develop flu vaccines

Emergent BioSolutions Inc., a U.S.-based developer and manufacturer of vaccines and antibody therapies, today launched its Singapore operations.

8 Oct 2010

Pandemic News and Research

Further Reading

Sinovac Biotech receives Drug Registration Certificate for seasonal influenza vaccine

New research shows flu virus with D222G mutation can cause pneumonia

Baxter third quarter net income increases 12% to $595 million

BioCryst to present intravenous peramivir data for influenza treatment at IDSA meeting

IRB approves CEL-SCI’s Multikine Phase III clinical trial for head and neck cancer

Gilead Sciences third quarter total revenues increase 8% to $1.94 billion

Egg allergy is no reason to avoid 2010-2011 flu vaccination

Biocon, Pfizer enter global agreement to commercialize Insulin analog products

Oseltamivir reduces mortality in influenza A/H5N1 patients

Medicago and PATH partner on development of broad coverage influenza vaccine

New evidence supports possible link between XMRV and prostate cancer

CEL-SCI receives Taiwanese IRB approval for Multikine Phase III trial in head and neck cancer

Loyola continues mandatory employee flu-vaccination policy for second straight year

BiondVax commences Multimeric-001 flu vaccine Phase IIa clinical study

HHS awards Sanofi Pasteur 3-year, $56.94M egg supply contract for pandemic vaccine preparedness

Scientists proves Yersinia pestis as causative agent for Black Death epidemics in European continent

Flu season looking 'typical,' CDC says

“Black Death” of the Middle ages blamed on bacteria

CDC issues new universal influenza vaccination recommendation for all Americans

Emergent BioSolutions and TLV form new joint venture to develop flu vaccines

Best practices - optimize qPCR processes for pathogen detection eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News